Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5412255 | 0.98 | CHRM5 (0.38) | CHRM5CHKACSF1RJAK1GBA1 | |
| SCHEMBL3223030 | 0.83 | GBA1 (0.50) | GBA1 | |
| Hydrochloric Acid SCHEMBL6582411 | 0.83 | BRD4 (0.47) | CHRM5CHKAGBA1BRD4HRH3 | |
| SCHEMBL2392197 | 0.80 | EP300 (0.38) | JAK1GBA1BRD4TDP1PDK1 | |
| Hydrochloric Acid SCHEMBL5394863 | 0.78 | JAK1 (0.40) | JAK1TDP1 | |
| SCHEMBL5650751 | 0.78 | EP300 (0.42) | GBA1HRH3HRH4TDP1 | |
| Hydrochloric Acid SCHEMBL5410395 | 0.77 | JAK1 (0.37) | CSF1RJAK1GBA1BRD4HRH3 | |
| SCHEMBL31381408 | 0.76 | EP300 (0.41) | GBA1TDP1PDK1 | |
| SCHEMBL27564890 | 0.75 | SLC6A2 (0.45) | MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL5401940 | 0.75 | PIM1 (0.40) | CSF1RJAK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294627-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | F11, SERPINC1, F2 | CHRM5 3740/4885CHKA 3721/4885CSF1R 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.